Obsidian Therapeutics, Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.

URL

https://obsidiantx.com

IPO date

Employees

Domiciled in

Incorporated in

Valuation

No data to show